COVID-19 vaccine-related adverse effects and perceptions in Haryana State of India
Keywords:
COVID-19 vaccine, Covishield, Covaxin, Adverse effect, PerceptionsAbstract
Background: The focus of this study was on any COVID-19 vaccines adverse effects, as well as perceptions about the vaccines. Among many, Covishield Covid-19 (ChAdOx1 nCoV-19) and Covaxin COVID-19 (BBV152) vaccines are some of the vaccines which have reached their advanced stages. These two brands are very common in India, and the majority of the already vaccinated populations in India comes from these two brands. Methods: It was a quantitative systemic randomized retrospective cohort kind of a study where only healthcare practitioners were targeted, especially the prescribers. Survey questionnaire was used as a tool of collecting the data from the voluntarily recruited participants. Results: Among the participants, males (106) were more than females (98). Different healthcare professionals: 100 (49.0%) were Physician/doctors; 36 (17.6%) were Pharmacists; 27 (13.2%) were Nurses; 23 (11.3%) were Medical Lab. Technicians and 18 (8.8%) were others. 123 participants reported not been affected by any side effects after taking the COVID-19 vaccines, in contrast, 81 participants reported to have experienced adverse effects after had taken the vaccines. Conclusion: This study showed that post-vaccination, of both first and second dose, adverse effects were mild to moderate, non-serious and non-life threatening.
Downloads
References
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021). Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 19, 155–170. DOI: 10.1038/s41579-020-00468-6
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., Xing, X., Xiang, N., et al. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus- Infected Pneuminia. New Englind Journal of Medicine, 382: 1199-1207. DOI: 10.1056/NEjMoa2001316.
He, F., Deng, Y., Li, W., (2020). Coronavirus disease 2019: What we know? Journal of Medicical Virology, 92(7): 719-725. DOI: 10.1002/jmv.25766.
Zhou, D., Zhang, P., Bao, C., Zhang, Y., Zhu, N. (2020) Emerging Understanding of Etiology and Epidemiology of the Novel Coronavirus (COVID-19) infection in Wuhan, China. Preprints, 2020020283. DOI: 10.20944/preprints202002.0283.v1).
Lone, S. A., Ahmad, A., (2020). COVID-19 pandemic- an African perspective, Emerging Microbes & Infections,9(1), 1300-1308, DOI: 10.1080/22221751.2020.1775132. http//doi.org/10.1080/22221751.2020.1775132
Rauf A., Abu-Izneid T., Olatunde A., Khalil A. A., Alhumaydhi F. A., Tufail T., Shariati M. A., Rebezow M., Almarhoon Z. M., Mabkhot Y. N.,Alsayari A., Rengasamy K. R.R.et al. 2020. COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. Int. J. Environ.Res. Public Health.17,8155; doi:103390/ijerph17218155. www.mdpi.com/journal/ijerph
Huang, C., Wang,Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Cao, B., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223), 497-506. DOI: 10.1016/S0140-673(20) 30183-5.
Rothan H. A., Byrareddy S. N. 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 109, 102433.
Yamamoto, V., Bolanos, J. F., Fiallos, J., Strand, S. E., Morris, K., Shahrokhinia, S., Cushing, T. R., Hopp, L., Tiwari, A., Hariri, R., Sokolov, R., Wheeler, C., Kaushik, A., Elsayegh, A., Eliashiv, D., Hedrick, R., Jafari, B., Johnson, J. P., Khorsandi, M., Gonzalez, N., Balakhani, G., Lahiri, S., Ghavidel, K., Amaya, M., Kloor, H., Hussain, N., Huang, E., Cormier, J., Wesson Ashford J., Wang, J. C, Yaghobian, S., Khorrami, P., Shamloo, B., Moon, C., Shadi, P., Kateb, B. COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications. (2020). J Alzheimers Dis. 77(2),459-504. DOI:10.3233/JAD-200831.
Schoeman, D., Fielding, B.C. (2019) Coronavirus envelope protein: current knowledge Virol J 16, 69 (2019). DOI:10.1186/s12985-019-1182-0
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu N. H., Nitsche, A., Müller, M. A., Drosten, C., Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052.
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., Meng, Y., Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, W. J., Wang, D., Xu, W., Holmes, E. C., Gao, G. F., Wu, G., Chen, W., Shi, W., Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 22;395(10224):565-574. DOI:10.1016/S0140-6736(20)30251-8.
Jiang, M. D., Zu, Z. Y., Schoepf, U. J., Savage, R. H., Zhang, X. L., Lu, G. M., & Zhang, L. J. (2020). Current Status of Etiology, Epidemiology, Clinical Manifestations and Imagings for COVID-19. Korean journal of radiology, 21(10), 1138–1149. DOI: 10.3348/kjr.2020.0526
Hadj Hassine, I. Covid-19 vaccines and variants of concern: A review. (2021). Rev Med Virol, 9;e2313. DOI: 10.1002/rmv.2313.
Milligan, I. D., Gibani, M. M., Sewell, R., et al. (2016) Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA. 2016;315(15):1610–1623. DOI:10.1001/jama.2016.4218
Matz, K. M., Marzi, A., Feldmann, H. (2019) Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Rev Vaccines, 18(12):1229-1242. DOI: 10.1080/14760584.2019.1698952.
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015). Polio Vaccination: Past, present and future. Future Microbiology, 10(5). DOI: 10.2217/FMB.15.19.
Keshavarz, M., Mirzaei, H., Salemi, M., Momeni, F., Mousavi, M. J., Sadeghalvad, M., Arjeini, Y., Solaymani-Mohammadi, F., Sadri Nahand, J., Namdari, H., Mokhtari-Azad, T., Rezaei, F. (2019). Influenza vaccine: Where are we and where do we go? Rev Med Virol, 29(1):e2014. DOI: 10.1002/rmv.2014.
www. Mohfw.gov.n/www.cowin.gov.in
https://www.medicalnewstoday.com/articles/oxford-astrazeneca-vaccine-what-to-know-about-side-effects
https://www.mpnrc.org/covaxin-vs-covishield/
https://www.bharatbiotech.com/covaxin.html
Barat Biotech International Limited. (2021). Restricted Use of COVAXINTM Under Clinical Trail Mode: Implementation Plan No: BBIL/COVAXINTM/2021. ICMR Journal, 4
Riad, A., Schünemann, H., Attia, S., Peričić, T. P., Žuljević, M. F., Jürisson, M., Kalda, R., Lang, K., Morankar, S., Yesuf, E. A., Mekhemar, M., Danso-Appiah, A., Sofi-Mahmudi, A., Pérez-Gaxiola, G., Dziedzic, A., Apóstolo, J., Cardoso, D., Marc, J., Moreno-Casbas, M., Wiysonge, C. S., Qaseem, A., Gryschek, A., Tadić, I., Hussain, S., Khan, M. A., Klugarova, J., Pokorna, A., Koščík, M., Klugar, M. (2021). COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines' Side Effects. Int J Environ Res Public Health, 18(15):7859. DOI:10.3390/ijerph18157859.
Beatty, A. L., Peyser, N. D., Butcher, X. E., et al. (2021) Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw Open, 4(12):e2140364. DOI:10.1001/jamanetworkopen.2021.40364.
Saeed, B. Q., Al-Shahrabi, R., Alhaj, S. S., Alkokhardi, Z. M., Adrees, A. O. (2021). Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis, 111:219-226. DOI: 10.1016/j.ijid.2021.08.013.
Wu, Q., Dudley, M. Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D., Yu, H. (2021). Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med, 19(1):173. DOI: 10.1186/s12916-021-02059-5.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.








